|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | +0.84% |
|
-3.23% | +14.29% |
| Mar. 19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
| Feb. 27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Aclaris Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 31.25 million compared to USD 29.75 million a year ago. Net loss was USD 88.48 million compared to USD 86.91 million a year ago.
Basic loss per share from continuing operations was USD 1.27 compared to USD 1.33 a year ago. Diluted loss per share from continuing operations was USD 1.27 compared to USD 1.33 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 85.52M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
ACLARIS THERAPEUTICS, INC. 
